Key result
Surgical management of obesity and pharmacological therapies such as naltrexone-bupropion are being evaluated for their impact on cardiovascular disease.
Key points are not available for this paper at this time.
Answers are grounded in this paper and cite their sources.
Ongoing evaluations of surgical obesity management and naltrexone-bupropion leave open net cardiovascular effects; randomized trials needed before practice change.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Vest et al. (2013) studied this question. Surgical management of obesity and pharmacological therapies such as naltrexone-bupropion are being evaluated for their impact on cardiovascular disease.
Synapse has enriched 10 related papers. Consider them for comparative context: